Immune Therapy of HPV-induced Cancers

Summary

Patients with advanced HPV- and p16INK4a-positive cancers will receive the peptide P16\_37-63 in combination with Montanide® ISA-51 VG so that an immune response directed against the tumor cells can be induced. The aim is to show that vaccination with P16\_37-63 is safe and can induce or enhance immune responses against p16INK4a.

Timeline

Start

2011-08

Primary completion

2015-01

Completion

2015-05

Drugs

Indications